BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35412132)

  • 1. Peptide-Based HIV Entry Inhibitors.
    Pu J; Wang Q; Jiang S
    Adv Exp Med Biol; 2022; 1366():15-26. PubMed ID: 35412132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The current progress in the development of HIV-1 fusion inhibitors].
    Shi WG; Jia QY; Liu KL
    Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Enfuvirtide, mechanism of action and pharmacological properties].
    Kapić E; Becić F; Zvizdić S
    Med Arh; 2005; 59(5):313-6. PubMed ID: 16134757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.
    Pu J; Wang Q; Xu W; Lu L; Jiang S
    Viruses; 2019 Aug; 11(8):. PubMed ID: 31374953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV entry and fusion inhibitors.
    Chantry D
    Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Entry inhibitors in the treatment of HIV-1 infection.
    Tilton JC; Doms RW
    Antiviral Res; 2010 Jan; 85(1):91-100. PubMed ID: 19683546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins.
    Steffen I; Pöhlmann S
    Curr Pharm Des; 2010; 16(9):1143-58. PubMed ID: 20030613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
    Zhu Y; Chong H; Yu D; Guo Y; Zhou Y; He Y
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV entry inhibitors: a new generation of antiretroviral drugs.
    Krambovitis E; Porichis F; Spandidos DA
    Acta Pharmacol Sin; 2005 Oct; 26(10):1165-73. PubMed ID: 16174430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.
    Fung HB; Guo Y
    Clin Ther; 2004 Mar; 26(3):352-78. PubMed ID: 15110129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20).
    Manfredi R; Sabbatani S
    Curr Med Chem; 2006; 13(20):2369-84. PubMed ID: 16918361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to enfuvirtide, the first HIV fusion inhibitor.
    Greenberg ML; Cammack N
    J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide and non-peptide HIV fusion inhibitors.
    Jiang S; Zhao Q; Debnath AK
    Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
    Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR
    J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enfuvirtide.
    Lalezari JP; Luber AD
    Drugs Today (Barc); 2004 Mar; 40(3):259-69. PubMed ID: 15148534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
    Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibitors of fusion: a new alternative in the treatment of HIV infection].
    Roca Villanueva B
    Med Clin (Barc); 2004 May; 122(17):659-60. PubMed ID: 15153345
    [No Abstract]   [Full Text] [Related]  

  • 19. Updating the use of synthetic peptides as inhibitors of HIV-1 entry.
    Gómara MJ; Haro I
    Curr Med Chem; 2014 Apr; 21(10):1188-200. PubMed ID: 23931277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 gp41: mediator of fusion and target for inhibition.
    Weiss CD
    AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.